Zai Lab Limited (ZLAB)

Market Cap	2.11B -43.2%
Revenue (ttm)	460.16M +15.3%
Net Income	-175.54M
EPS	-1.60
Shares Out	110.64M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	629,092
Open	18.57
Previous Close	18.37
Day's Range	18.56 - 19.13
52-Week Range	15.96 - 44.34
Beta	0.88
Analysts	Strong Buy
Price Target	51.00 (+167.58%)
Earnings Date	Feb 26, 2026

About ZLAB

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacter...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 20, 2017
• Employees: 1,784
• Stock Exchange: NASDAQ
• Ticker Symbol: ZLAB
• Website: https://www.zailaboratory.com

Financial Performance

In 2025, Zai Lab's revenue was $460.16 million, an increase of 15.33% compared to the previous year's $398.99 million. Losses were -$175.54 million, -31.73% less than in 2024.

Analyst Summary

According to 5 analysts, the average rating for ZLAB stock is "Strong Buy." The 12-month stock price target is $51.0, which is an increase of 167.58% from the latest price.

Price Target

$51.0

(167.58% upside)

Analyst Consensus: Strong Buy